UNSPSC 51263155: Bucumolol hydrochloride

This classification denotes a beta-adrenergic blocking agent with the molecular formula C17H23NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U2Z7867QU7, chemically known as 5-methyl-8-(2-hydroxy-3-t-butylaminopropoxy)coumarin hydrochloride, dl- but more generally known as bucumolol hydrochloride, which bears US NIH Compound Identifier 169786. European Medicines Agency schedules Bucumolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21960.

Most nations, for tariff and trade purposes, schedule bucumolol hydrochloride under HS 29322985. As of Q4 2014, BUCUMOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1CCC(C2C1CCC(=O)O2)OCC(CNC(C)(C)C)O.CL.

UNSPSC 51263155 Bucumolol hydrochloride is a Commodity code that shows minimal recent state and local procurement activity aligned with its nominal pharmaceutical scope. The single recent opportunity on record — Seminole County, Florida's IFB 60459723LAS — solicits naloxone and drug deactivation systems rather than bucumolol hydrochloride, indicating a significant mismatch between the code's assigned category and the work actually being procured. State and local buyers do not appear to be using this code to source bucumolol hydrochloride or related pharmaceutical products at present.

Seminole County issued the naloxone and drug deactivation systems IFB on June 30, 2026, with a response deadline of July 26, 2023 (date discrepancy noted in source), seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The procurement required electronic submission through the county's e-Procurement Portal, included drug-free workplace certification and E-Verify compliance, and carried potential FEMA funding with associated federal compliance requirements. This single opportunity does not establish meaningful geographic spread or issuing-body concentration under the bucumolol hydrochloride code. The code shows no recent relevant activity for pharmaceutical procurement professionals to pursue.